Which has the lower trailing P/E, AUPH or PGNY?

AUPH has the lower trailing P/E: AUPH trades at 6.86 and PGNY at 28.16. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, AUPH or PGNY?

Over the past five years, AUPH grew revenue faster — AUPH at a 40.17% CAGR versus PGNY at 23.84%.

Is AUPH or PGNY more profitable?

AUPH runs the higher net margin — AUPH at 100.84% versus PGNY at 6.00%.

How have AUPH and PGNY total returns compared?

Over the past 5 years, AUPH delivered -5.88% and PGNY delivered -14.83% annualized total return. Past performance doesn't predict future results.

Aurinia Pharmaceuticals Inc. (AUPH) vs Progyny, Inc. (PGNY)

A side-by-side comparison of Aurinia Pharmaceuticals Inc. and Progyny, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

AUPH

Aurinia Pharmaceuticals Inc.

$2.02B

$15.72HealthcareDelayed quote: Oct 6, 2026, 2:05 PM EDT

PGNY

Progyny, Inc.

$2.03B

$25.91HealthcareDelayed quote: Oct 6, 2026, 2:00 PM EDT

Total return — AUPH vs PGNY

growth of $100 · dividends reinvested · last 7y

AUPH +225.5% (+18.4%/yr)PGNY +62.2% (+7.2%/yr)AUPH compounded faster over this window

AUPH PGNY

AUPH vs PGNY: by the numbers

•PGNY is the larger company ($2.03B vs $2.02B market cap).
•AUPH trades at the lower trailing earnings multiple (6.86 vs 28.16 P/E), one valuation lens rather than an overall verdict.
•AUPH converts more revenue to profit (100.84% vs 6.00% net margin).
•AUPH grew revenue faster over the past five years (40.17% vs 23.84% CAGR).

Metrics side by side

Valuation

Metric	AUPH	PGNY
P/E ratio	6.86	28.16
Forward P/E	16.65	20.14
PEG ratio	N/A	4.20
P/S ratio	6.49	1.55
P/B ratio	3.29	4.48
EV / EBITDA	11.18	15.95
FCF yield	8.59%	10.74%

Profitability

Metric	AUPH	PGNY
Gross margin	90.36%	24.57%
Operating margin	37.06%	8.55%
Net margin	100.84%	6.00%
ROE	51.09%	17.35%
ROIC	21.77%	15.47%

Growth (annualized)

Metric	AUPH	PGNY
Revenue CAGR (5Y)	40.17%	23.84%
EPS CAGR (5Y)	N/A	4.72%
FCF CAGR (5Y)	N/A	73.48%
Total return CAGR (5Y)	-5.88%	-14.83%

Frequently asked

Which has the lower trailing P/E, AUPH or PGNY?: AUPH has the lower trailing P/E: AUPH trades at 6.86 and PGNY at 28.16. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, AUPH or PGNY?: Over the past five years, AUPH grew revenue faster — AUPH at a 40.17% CAGR versus PGNY at 23.84%.
Is AUPH or PGNY more profitable?: AUPH runs the higher net margin — AUPH at 100.84% versus PGNY at 6.00%.
How have AUPH and PGNY total returns compared?: Over the past 5 years, AUPH delivered -5.88% and PGNY delivered -14.83% annualized total return. Past performance doesn't predict future results.

Go deeper

Full AUPH analysis Full PGNY analysis Interactive comparison tool

Dig into the metrics

Aurinia Pharmaceuticals P/E ratio Progyny P/E ratio Aurinia Pharmaceuticals ROE Progyny ROE Aurinia Pharmaceuticals operating margin Progyny operating margin Aurinia Pharmaceuticals revenue growth Progyny revenue growth Aurinia Pharmaceuticals free cash flow Progyny free cash flow

Aurinia Pharmaceuticals & Progyny appear in these rankings

Fastest Revenue Growth Stocks Highest ROE Stocks Highest ROIC Stocks Highest Operating Margin Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.